The Evaluation of Vision Related Quality of Life in Patients with Retinitis Pigmentosa after Suprachoroidal Umbilical Cord Derived Mesenchymal Stem Cell Treatment

N. Kahraman, A. Oner
{"title":"The Evaluation of Vision Related Quality of Life in Patients with Retinitis Pigmentosa after Suprachoroidal Umbilical Cord Derived Mesenchymal Stem Cell Treatment","authors":"N. Kahraman, A. Oner","doi":"10.4236/ojoph.2021.113016","DOIUrl":null,"url":null,"abstract":"Background: The aim of this study was to evaluate vision related quality of life (VRQoL) in patients with retinitis pigmentosa (RP) after suprachoroidal umbilical cord derived mesenchymal stem cell (UC-MSC) treatment. Methods: The patients were evaluated regarding to the VRQoL before the treatment and at the end of the first year. The study was performed in an affiliated hospital of a university between 2018 and 2020. The patients were operated by a single surgeon and evaluated at baseline and at first, sixth and twelfth month after stem cell implantation. To assess patients’ subjective visual situation, we used Impact of Vision Impairment (IVI) Profile 28-item questionnaire. It basically evaluated vision-related activities in three subscales: “reading and accessing information”, “mobility and independence” and “emotional well-being”. This test is established to assess VRQoL in low vision patients. Results: A total of 123 people, ranging in age from 18 to 48 years, participated in the study and 43.9% (n = 54) were women. The study patients were followed up for one year and the questionnaire was filled by patients at baseline and one year after surgery. In all groups, no difficulty was observed in understanding the questionnaire. The results showed significant improvements in VRQoL after stem cell treatment (p < 0.05). The analysis of each subscale score including “reading and accessing information”, “mobility and independence” and “emotional well-being” before and after treatment showed significant improvements in all subscale scores (p < 0.05). Conclusions: IVI 28 item questionnaire seems to be an effective test for the assessment of VRQoL in low vision patients. The suprachoroidal implantation of UC-MSC for the treatment of RP can improve the quality of life of these patients.","PeriodicalId":60672,"journal":{"name":"眼科学期刊(英文)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"眼科学期刊(英文)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4236/ojoph.2021.113016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The aim of this study was to evaluate vision related quality of life (VRQoL) in patients with retinitis pigmentosa (RP) after suprachoroidal umbilical cord derived mesenchymal stem cell (UC-MSC) treatment. Methods: The patients were evaluated regarding to the VRQoL before the treatment and at the end of the first year. The study was performed in an affiliated hospital of a university between 2018 and 2020. The patients were operated by a single surgeon and evaluated at baseline and at first, sixth and twelfth month after stem cell implantation. To assess patients’ subjective visual situation, we used Impact of Vision Impairment (IVI) Profile 28-item questionnaire. It basically evaluated vision-related activities in three subscales: “reading and accessing information”, “mobility and independence” and “emotional well-being”. This test is established to assess VRQoL in low vision patients. Results: A total of 123 people, ranging in age from 18 to 48 years, participated in the study and 43.9% (n = 54) were women. The study patients were followed up for one year and the questionnaire was filled by patients at baseline and one year after surgery. In all groups, no difficulty was observed in understanding the questionnaire. The results showed significant improvements in VRQoL after stem cell treatment (p < 0.05). The analysis of each subscale score including “reading and accessing information”, “mobility and independence” and “emotional well-being” before and after treatment showed significant improvements in all subscale scores (p < 0.05). Conclusions: IVI 28 item questionnaire seems to be an effective test for the assessment of VRQoL in low vision patients. The suprachoroidal implantation of UC-MSC for the treatment of RP can improve the quality of life of these patients.
脉络膜上脐带源性间充质干细胞治疗后色素性视网膜炎患者视力相关生活质量的评价
背景:本研究的目的是评估视网膜色素变性(RP)患者在脉络膜上脐带源性间充质干细胞(UC-MSC)治疗后的视力相关生活质量(VRQoL)。方法:分别在治疗前和治疗一年末对患者进行VRQoL评价。该研究于2018年至2020年在一所大学的附属医院进行。患者由一名外科医生进行手术,并在基线和干细胞植入后的第一个月、第6个月和第12个月进行评估。为了评估患者的主观视觉状况,我们使用了视力损害影响(IVI)概况28项问卷。它基本上通过“阅读和获取信息”、“移动和独立”和“情绪健康”三个子量表来评估视觉相关活动。本测试旨在评估低视力患者的VRQoL。结果:共有123人参与研究,年龄在18 - 48岁之间,其中43.9% (n = 54)为女性。研究患者随访1年,并在基线和术后1年填写问卷。在所有组中,没有观察到理解问卷的困难。结果显示干细胞治疗后VRQoL有显著改善(p < 0.05)。对治疗前后“阅读与获取信息”、“行动能力与独立性”、“情绪幸福感”各分量表得分进行分析,结果显示治疗前后各分量表得分均有显著改善(p < 0.05)。结论:IVI 28项问卷是评估低视力患者VRQoL的有效方法。脉络膜上植入UC-MSC治疗RP可提高患者的生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
232
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书